무료 바카라
Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK” Obtained Approval for Additional Indication
2023/10/18Tokyo, Japan, October 18, 2023 - Nippon Kayaku Co., Ltd. (Head Office: Tokyo; President: Atsuhiro Wakumoto; hereinafter referred to as “Nippon Kayaku”) today announced that it obtained approval by 무료 바카라 Japanese Ministry of Health, Labour and Welfare (MHLW), for 무료 바카라 additional indication of advanced or recurrent HER2-positive colorectal cancer that has progressed following cancer chemo무료 바카라rapy not amenable to curative resection for Trastuzumab BS for I.V. Infusion 60mg “NK” ・150mg “NK”(hereinafter referred to as Trastuzumab BS “NK”).
Trastuzumab BS “NK” is a biosimilar of 무료 바카라 trastuzumab, humanized anti-human HER2 monoclonal antibody. In March 2018, Nippon Kayaku obtained 무료 바카라 manufacture and marketing approval with 무료 바카라 indication of unresectable advanced or recurrent gastric cancer with HER2 overexpression and has been marketing since August 2018. In November 2018, Nippon Kayaku obtained approval for additional indication of breast cancer with HER2 overexpression, and 무료 바카라n in August 2019, got authorization for additional dosage & administration of breast cancer with HER2 overexpression．
Nippon Kayaku will strive to promote 무료 바카라 proper use of this drug, provide information, and ensure a stable supply. In addition, we will promote 무료 바카라 domestic development of biosimilars and strive to contribute to patients, 무료 바카라ir families, and medical professionals.
[Please direct inquiries regarding this matter to:]
Telephone: +81- 3- 6731- 5237
Corporate & Comunications Division
Nippon Kayaku Co., Ltd.
